Share
Share today's newsletter with a colleague
and get credit if they sign up for SmartBrief.
Referral Count:
0
Story being shared
Metformin outperforms glipizide in preventing CVD events in diabetes
Long-term metformin treatment was associated with fewer cardiovascular events than glipizide therapy in type 2 diabetes patients with a history of coronary artery disease, according to a study in Diabetes Care. Data on 304 patients showed 35.1% of glipizide-treated patients experienced cardiovascular events at five years, compared with 25% of metformin-treated patients.
Or we can send an email on your behalf